Financials
Reported figures only · latest: Q4 2024
USD · IFRS
Source: SEC XBRL filings
· latest filing
The long view
Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income11 fiscal yearsShow the numbers
| Year | Revenue | Net income |
|---|
| FY24 | $61.6M | −$31.8M |
|---|
| FY23 | $56.8M | −$24M |
|---|
| FY22 | $62.5M | −$41M |
|---|
| FY21 | $81.1M | $875K |
|---|
| FY20 | $102M | −$6.4M |
|---|
| FY19 | $90.4M | −$28.9M |
|---|
| FY18 | $97M | −$22.1M |
|---|
| FY17 | $99.1M | −$40.3M |
|---|
| FY16 | $99.6M | −$100.6M |
|---|
| FY15 | $100.2M | $21.8M |
|---|
| FY14 | - | - |
|---|
MarginsShare of revenue- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|
| FY24 | 34.8% | −34.4% | −51.6% |
|---|
| FY23 | 34.2% | −47.6% | −42.3% |
|---|
| FY22 | 27.6% | −30.9% | −65.6% |
|---|
| FY21 | 41.2% | 4.9% | 1.1% |
|---|
| FY20 | 47.6% | 0.1% | −6.3% |
|---|
| FY19 | 42.2% | −26.7% | −32% |
|---|
| FY18 | 42.7% | −20.8% | −22.8% |
|---|
| FY17 | 42.3% | −38% | −40.6% |
|---|
| FY16 | 43.7% | −40% | −101% |
|---|
| FY15 | 46.4% | 13.5% | 21.8% |
|---|
| FY14 | - | - | - |
|---|
Free cash flowOperating cash flow minus capital expenditureShow the numbers
| Year | Free cash flow |
|---|
| FY24 | −$4.6M |
|---|
| FY23 | −$12.4M |
|---|
| FY22 | −$2M |
|---|
| FY21 | $11.4M |
|---|
| FY20 | $20.6M |
|---|
| FY19 | $3.3M |
|---|
| FY18 | −$299K |
|---|
| FY17 | $4.4M |
|---|
| FY16 | $6M |
|---|
| FY15 | $6.1M |
|---|
| FY14 | - |
|---|
Returned to shareholdersDividends paid and shares bought backShow the numbers
| Year | Dividends | Buybacks |
|---|
| FY24 | - | - |
|---|
| FY23 | - | - |
|---|
| FY22 | - | - |
|---|
| FY21 | - | - |
|---|
| FY20 | - | - |
|---|
| FY19 | - | - |
|---|
| FY18 | - | $434K |
|---|
| FY17 | - | $7.8M |
|---|
| FY16 | - | $9.3M |
|---|
| FY15 | $5.1M | - |
|---|
| FY14 | - | - |
|---|
Net margin vs the sectorMedian of Healthcare companies filing with the SEC- Trinity Biotech
- Healthcare median
Show the numbers
| Year | Trinity Biotech | Healthcare median |
|---|
| FY24 | −51.6% | −47% |
|---|
| FY23 | −42.3% | −58% |
|---|
| FY22 | −65.6% | −80.4% |
|---|
| FY21 | 1.1% | −71.9% |
|---|
| FY20 | −6.3% | −62.2% |
|---|
| FY19 | −32% | −46.3% |
|---|
| FY18 | −22.8% | −49.6% |
|---|
| FY17 | −40.6% | −45.9% |
|---|
| FY16 | −101% | −36% |
|---|
| FY15 | 21.8% | −38.4% |
|---|
| FY14 | - | −35.5% |
|---|